Medical/Pharmaceuticals

JOGO HEALTH (INDIA) GRANTED WORLD'S FIRST JOINT COMMISSION INTERNATIONAL(JCI) ACCREDITATION FOR A DIGITAL CLINIC

* Chicago based Joint Commission helps healthcare organizations improve clinical and operational processes and build staff competencies and knowledge of leading practices. * More than 22,000 US health care organizations are accredited by Joint Commission and a majority of US state government...

2023-11-28 16:01 1538

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)

YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase II, open-label, multicenter, single-arm studies for Disitamab Vedotin (RC48-C005 an...

2023-11-28 09:48 2133

Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA

SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...

2023-11-28 08:00 1636

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology

* AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides accurate prognosis prediction in stage II–III colon cancer SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and...

2023-11-27 22:05 1477

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...

2023-11-27 21:30 1453

XtalPi and HKU's Advanced Biomedical Instrumentation Centre Sign MoU to Accelerate Deep Tech Commercialization

CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- XtalPi Inc. (XtalPi) and the Advanced Biomedical Instrumentation Centre (ABIC or the Centre) at the University of Hong Kong (HKU) have entered a memorandum of understanding (MoU) that outlines a roadmap for scientific collaboration and commercializat...

2023-11-27 21:20 1911

"Anti-Choke Mug" - Chula Innovation for Neuro Patients to Drink Water Confidently

BANGKOK, Thailand, Nov. 27, 2023 /PRNewswire/ -- Chula  Medicine designed an anti-choke mug  with calculated angle, amount, and time of water flow from the mug to the patient's lips hoping to reduce choking that may lead ...

2023-11-27 12:23 2037

Fovia Ai to Showcase Optimized AI Visualization at IAIP Exhibit, RSNA 2023

Fovia Ai Provides Efficient AI Results in One Unified Viewer CHICAGO, Nov. 26, 2023 /PRNewswire/ -- Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for over two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced th...

2023-11-26 22:00 1983

Vieworks Showcases X-ray Imaging Excellence: RSNA 2023 Spotlight

ANYANG, South Korea, Nov. 25, 2023 /PRNewswire/ -- Vieworks, a renowned digital x-ray imaging solutions provider, is set to unveil pioneering advancements at RSNA 2023 inChicago (Booth 1723, November 26th-29th). Building on the success of prior RSNA exhibitions, Vieworks will present its comprehe...

2023-11-25 04:00 3553

DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia

- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China  SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...

2023-11-24 22:00 3683

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou,China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the firs...

2023-11-24 19:57 2312

China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation

SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) ofChina has accepted the...

2023-11-24 19:00 2241

Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment

Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of early iron deficiency diagnosis and treatment and its impact on quality of life ST. GALLEN, SWITZERL...

2023-11-24 15:00 3968

CooperVision to host 3rd APAC Myopia Management Symposium in Taiwan Region

Held in partnership with Universal Eye Center, the hybrid event is expected to hostmore than 2,000 renowned Myopia Management experts across APAC and globally SINGAPORE, Nov. 24, 2023 /PRNewswire/ -- CooperVision , a global leader in myopia management, will host it...

2023-11-24 14:25 2362

Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the ...

2023-11-24 12:54 3948

Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang

HANGZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Broncus(2216.HK) is pleased to announce that, onNovember 23 2023 Broncus Hangzhou (a whollyowned subsidiary of Broncus, as Transferee) has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equ...

2023-11-24 09:19 4667

China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2023-11-24 08:42 4172

Neurophet to showcase brain image analysis technology at RSNA 2023

- Introducing Alzheimer's disease related brain image analysis technology including Neurophet AQUA and Neurophet SCALE PET - Plans to launch analysis technology for infant brain image and cerebrovascular disease SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ -- Neurophet, an artificial intellig...

2023-11-23 22:00 2044

Medica 2023: Fapon Accelerates the Development of its Diagnostic Ecosystem

DUSSELDORF, Germany, Nov. 23, 2023 /PRNewswire/ -- Fapon, a global leading life sciences organization, unveiled its innovative integrated solutions for diagnostics and forged strategic partnerships at the 55th International Hospital and Medical Equipment Exhibition (MEDICA 2023), held fromNovembe...

2023-11-23 17:27 2608

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL...

2023-11-23 16:04 4496
1 ... 120121122123124125126 ... 611